Tags : Platform


Ziopharm Oncology’s Controlled IL-12 Platform Receives EMA’s COMP Positive Recommendation

Shots: EMA’s Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending Ziopharm’s Controlled IL-12 platform (Ad-RTS-hIL-12 + veledimex) for ODD candidate for the treatment of glioma EMA’s ODD provides regulatory and financial incentives to the company for developing & commercializing therapies for life-threatening diseases no more than five in 10,000 persons in […]Read More


Agilent Technologies Acquires ACEA Biosciences to Strengthen Platform and Capabilities

Shots: ACEA to receive $250M in upfront cash as a total deal value, adding a differentiated portfolio and organizational capabilities in cell analysis Agilent will get hold of ACEA’s CFDA and CE-IVD labelled cytometer configuration, i.e. NovoCyte flow cytometer and xCELLigence Real-Time Cell analyzer used for monitoring growth, function, and cellular responses of cells The […]Read More